FLAG Therapeutics to Present in San Francisco
RALEIGH, Dec 21, 2018 -- FLAG Therapeutics Inc. (www.flagtherapeutics.com), a clinical-stage oncology company with two novel classes of small molecules, announced that it will present in San Francisco at two events coinciding with the 2019 J.P. Morgan Annual Healthcare Conference.
Sunday, Jan. 6, FLAG Therapeutics President and Chief Executive Officer (CEO) Frank Sorgi, Ph.D., MBA, will present at the Wheelhouse RD/Analysts event, “Private Companies Revolutionizing Medicine.” Dr. Sorgi will focus on FLAG’s innovative approach of combining two major classes of anti-cancer drugs — anti-angiogenic and anti-tubulin (AA/AT) — into a single, water-soluble small molecule that passes the blood-brain barrier.
Wednesday, Jan. 9, 2019, FLAG Therapeutics Director of Corporate Development James Bauler will present at the Biotech Showcase™ on FLAG’s two novel classes of bi-specific small molecules for orphan oncology, specifically for the treatment of glioblastoma and pancreatic cancers.
Wheelhouse: “Private Companies Revolutionizing Medicine”
Date: Sunday, Jan. 6, 2019
Time: 1:00 p.m.
Venue: JW Marriott San Francisco Union Square, 515 Mason Street, San Francisco, Calif.
Room: Skyline Room - 21st Floor
Date: Wednesday, Jan. 9, 2019
Time: 10:30 a.m.
Venue: Hilton San Francisco Union Square Hotel, 333 O'Farrell Street, San Francisco, Calif.
Room: Franciscan D (Ballroom Level)
About FLAG Therapeutics
FLAG Therapeutics Inc., headquartered in Raleigh, N.C., is a clinical stage oncology company focused on the development of therapies based on two novel classes of small-molecule, water-soluble drugs. In vivo studies suggest that both classes of compounds —anti-angiogenic and anti-tubulin (AA/AT) and Purine Synthesis Inhibitors — hold the potential to treat multiple cancer types with greater safety and efficacy than conventional therapies. FLAG Therapeutics has obtained exclusive worldwide rights to these compounds from Duquesne University. To learn more about FLAG Therapeutics, please visit: www.flagtherapeutics.com.
James Bauler, Director of Corporate Development
Phone: (828) 719-8279